IP Library Granted Patent US 12,679,863
Granted Patent B2
US 12,679,863 · App. 17/764,354 · Granted Jul 14, 2026

Peptide purification formulations and methods

Inventors: Sergei Snovida (Rockford, IL); Ryan Bomgarden (Winnebago, IL); Amarjeet Flora (Woodstock, IL)
Assignee: Life Technologies Corporation
C07K1/18G01N1/34G01N33/6848G01N2030/062
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,679,863
App. No.
17/764,354
Filed
Mar 28, 2022
Granted
Jul 14, 2026
Kind
B2
Art Unit
1656
USPC
530/416
Abstract

Improved formulations for purification of peptide from biological samples and methods and kits for purifying peptides from biological samples (e.g., cells and tissues), as well as use of purified peptides (e.g., polypeptides derived from protein digests) in mass spectrometry (e.g., LC-MS) applications are described.

Claims (26)

1 . A method of purifying peptides from a biological sample, comprising:

(a) contacting the biological sample with a hydrophobic, polymer-based cation exchange material under acidic conditions, such that the biological sample binds to the cation exchange material, wherein the biological sample comprises:

(i) at least one peptide,

(ii) at least one monovalent cationic contaminant and/or a at least one hydrophobic contaminant, and

(iii) at least one hydrophilic contaminant;

(b) washing the cation exchange material with a first volatile acidic solution, wherein the first volatile acidic solution comprises 20% or less (v/v) volatile organic solvent, water, and a first volatile acid, such that the at least one peptide is retained on the cation exchange material and the at least one hydrophilic contaminant is removed from the cation exchange material;

(c) washing the cation exchange material with a first volatile salt solution comprising a second volatile acidic solution, and a first volatile base solution, wherein the second volatile acidic solution comprises greater than 20% (v/v) volatile organic solvent, and water,

such that the at least one peptide is retained on the cation exchange material and the at least one monovalent cationic and/or the at least one hydrophobic contaminant is removed from the cation exchange material; and

(d) eluting the retained peptide from the cation exchange material with a volatile alkaline or neutral solution, wherein the volatile alkaline or neutral solution comprises a volatile organic solvent, water, and a volatile compound selected from a first or a second volatile base, a first or a second volatile salt, and a combination thereof.

2 . The method of claim 1 , wherein the hydrophilic contaminant is a neutral contaminant, an anionic contaminant, or a combination thereof.

3 . The method of claim 1 , wherein the biological sample further comprises a salt, detergent, a lipid, a small neutral molecule, or a combination thereof.

4 . The method of claim 1 , comprising contacting the sample with the hydrophobic, polymer-based cation exchange material at a pH 1-5.

5 . The method of claim 1 , comprising washing the cation exchange material at a pH 1-5.

6 . The method of claim 1 , comprising eluting the sample from the cation exchange material at greater than pH 5.

7 . The method of claim 1 , wherein the monovalent cationic contaminant is selected from the group consisting of ammonium, sodium, potassium, tris(hydroxymethyl)aminomethane (tris), hydroxylamine, ethanolamine, HEPES (4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid), PIPES (piperazine-N,N′-bis(2-ethanesulfonic acid)), EPPS (4-(2-Hydroxyethyl)-1-piperazinepropanesulfonic acid), glycine, a mass tag, and a combination thereof.

8 . The method of claim 1 , wherein the monovalent cationic contaminant is or comprises a mass tag or derivative thereof.

9 . The method of claim 1 , wherein hydrophobic contaminant is a lipid or a detergent.

10 . The method of claim 1 , wherein the hydrophilic contaminant is a salt, nucleic acid, or a carbohydrate.

11 . The method of claim 1 , further comprising treating the biological sample with a proteolytic enzyme to produce the peptide prior to contacting the biological sample with the cation exchange material.

12 . The method of claim 1 , wherein the hydrophobic, polymer-based cation exchange material is sulfonated divinyl benzene polystyrene, sulfonated polydivinyl benzene, or sulfonated divinyl benzene/polystyrene/pyrrolidone resin.

13 . The method of claim 1 , wherein the first and/or second volatile acid is selected from the group consisting of formic acid, acetic acid, trifluoracetic acid, trichloroacetic acid.

14 . The method of claim 1 , wherein the first and/or second volatile base is selected from the group consisting of trimethylamine, ammonia, triethylamine, piperidine, and butylamine.

15 . The method of claim 1 , wherein the volatile organic solvent is selected from the group consisting of acetonitrile, methanol, ethanol, n-propanol, iso-propanol, acetone, and a combination thereof.

16 . The method of claim 1 , wherein the sample comprises two or more peptides, a digested protein, or a polypeptide, a labeled peptide, a labeled peptide digest, a mass tag labeled peptide, a mass tag labeled peptide digest, a tandem mass tag (TMT)-labeled peptide, or a tandem mass tag (TMT)-labeled peptide digest.

17 . The method of claim 11 , wherein the proteolytic enzyme is trypsin, Lys-C, AspN, or GluC.

18 . The method of claim 1 , wherein the first and/or second volatile salt is selected from ammonium acetate, ammonium formate, ammonium trifloroacetate, triethylammonium formate, triethylammonium acetate, triethylammonium trifluoroacetate and ammonium bicarbonate.

Assignments (2)
MERGER Recorded Mar 11, 2026
From: PIERCE BIOTECHNOLOGY, INC.
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 075052/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2022
From: SNOVIDA, SERGEI; BOMGARDEN, RYAN; FLORA, AMARJEET
To: PIERCE BIOTECHNOLOGY, INC.
Reel/Frame 062177/0113 →
Continuity (2)
Provisional Application 62914796 · Oct 14, 2019
Related Publication 20220396598A1 · Dec 15, 2022
References Cited (45)
US 20040009567A1 · Duewel et al. · 2004 [cited by applicant]
US 20090148435A1 · Lebreton et al. · 2009 [cited by applicant]
US 20120231537A1 · Templeton et al. · 2012 [cited by applicant]
US 20130011925A1 · Gilar et al. · 2013 [cited by applicant]
US 20130079272A1 · Liu et al. · 2013 [cited by applicant]
US 20130309689A1 · Rogers et al. · 2013 [cited by applicant]
US 20150087073A1 · Chambers et al. · 2015 [cited by applicant]
US 20180078876A1 · Wang et al. · 2018 [cited by applicant]
US 20180201644A1 · Kulak et al. · 2018 [cited by applicant]
CN 1176659A · 1998 [cited by applicant]
CN 101333244A · 2008 [cited by applicant]
CN 102239175A · 2011 [cited by applicant]
CN 103687790A · 2014 [cited by applicant]
CN 107849085A · 2018 [cited by applicant]
EP 3115369A1 · 2017 [cited by applicant]
JP 2011502161A · 2011 [cited by applicant]
JP 2011519560A · 2011 [cited by applicant]
JP 2013530156A · 2013 [cited by applicant]
WO WO2008148645A1 · 2008 [cited by applicant]
WO WO2009058812A1 · 2009 [cited by applicant]
WO WO2012058619A1 · 2012 [cited by applicant]
WO WO2014066471A1 · 2014 [cited by applicant]
WO WO2015059478A1 · 2015 [cited by applicant]
WO WO2016149088A1 · 2016 [cited by applicant]
WO WO2017005898A1 · 2017 [cited by applicant]
Kalocsay. “APEX Peroxidase-Catalyzed Proximity Labelling and Multiplexed Quantitative Proteomics.” Proximity Labeling Methods and Protocols. Eds. Sunbul and Jaschke, Humana Press. (Year: 2008). [cited by examiner]
Kulak N.A., et al., “Minimal, Encapsulated Proteomic-Sample Processing Applied to Copy-Number Estimation in Eukaryotic Cells, ” Nature Methods, Mar. 2014, vol. 11, No. 3, pp. 319-324. [cited by applicant]
Zhao Z., et al., “A Novel Method of Preparation Samples for Mass Spectrometry Analysis of Histones,” China Academic Journal, Oct. 15, 2013, vol. 23, No. 5, pp. 59-63. [cited by applicant]
Adiga R et al., “Point-of-care production of therapeutic proteins of good-manufacturing-practice quality”, Nature Biomedical Engineering, Nature Publishing Group UK, London, vol. 2, No. 9, Jul. 9, 2018 (Jul. 9, 2018), p… [cited by applicant]
Agilent Technologies: “Agilent Bond Elut Plexa and Polymeric SPE Selection Guide,” The Measure of Confidence, 2011, 24 pages. [cited by applicant]
Agilent Technologies: “Agilent's New Mixed-Mode Cation Exchange Polymer Solid-Phase Extraction Cartridges: SampliQ SCX,” Agilent Technologies—Technical Note, 2008, 4 pages. [cited by applicant]
Balcke G.U., et al., “An UPLC-MS/MS Method for Highly Sensitive High-Throughput Analysis of Phytohormones in Plant Tissues,” Plant Methods, 2012, vol. 8, No. 47, 11 pages. [cited by applicant]
Borner G H, et al., “Using In-Solution Digestion, Peptide Fractionation, and a Q Exactive Mass Spectrometer to Analyze the Proteome of Clathrin-Coated Vesicles,” Cold Spring Harbor Protocols, Nov. 2014, vol. 11, pp. 119… [cited by applicant]
Chambers E.E., “Improving the Sensitivity and Specificity of LC/MS to Enable Bioanalysis of Therapeutic and Endogenous Proteins and Peptides,” Analytical and Environmental Sciences Research Division School of Biomedical… [cited by applicant]
Danaceau J.P., et al., “Removal of Pharmaceutical Dosing Excipients from Plasma Samples using Mixed-Mode Solid Phase Extraction (SPE),” Waters the Science of What's Possible, 2012, 1 page. [cited by applicant]
Gad S.C., “Preclinical Development Handbook,” ADME and Biopharmaceutical Properties, Wiley, 2008, 1347 pages. [cited by applicant]
Hui Y., “Development, Validation and Application of Analytical Methods to Measure Prognostic Biomarkers in Patients Receiving on-Pump Coronary Artery Bypass Grafting Surgery,” The University of British Columbia, 2013, 2… [cited by applicant]
Jenkins K.M., et al., “Mixed-Mode Solid-Phase Extraction Procedures for the Determination of MDMA and Metabolites in Urine Using LC-MS, LC-UV, or GC-NPD,” Journal of Analytical Toxicology, 2004, vol. 28, pp. 50-58. [cited by applicant]
Mazanek M., et al., “A New Acid Mix Enhances Phosphopeptide Enrichment on Titanium-and Zirconium Dioxide for Mapping of Phosphorylation Sites on Protein Complexes,” Journal of Chromatography, 2010, pp. 515-524. [cited by applicant]
PCT/US2020/055368, International Search Report and Written Opinion, Feb. 5, 2021, 14 pages. [cited by applicant]
Waters: “Chromatography Columns and Supplies Catalog,” The Science of what's Possible, 2008, 289 pages. [cited by applicant]
Waters: “ProteinWorks μElution SPE Clean-up Kit,” Waters MCX flyer, Care and Use Manual, Jan. 2016, 8 pages. [cited by applicant]
Wiederin J.L., et al., “Plasma Proteomic Analysis of Simian Immunodeficiency Virus Infection of Rhesus Macaques,” Journal of Proteome Research, Sep. 3, 2010, 9(9), pp. 4721-4731. [cited by applicant]
Williams L., et al., “The Use of Mixed-Mode SPE to Minimize LC-MS Matrix Effects Due to Dosing Vehicles,” Biotage, 2006, 6 pages. [cited by applicant]
Yuan L, et al., “Systematic investigation of orthogonal SPE sample preparation for the LC-MS/MS bioanalysis of a monoclonal antibody after pellet digestion.”, Bioanalysis, 2013, vol. 5, No. 19, pp. 2379-2391. [cited by applicant]